- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04842734
Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease
Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Eyalet/Yerleşke
-
İstanbul, Eyalet/Yerleşke, Turkey, 34865
- Yeditepe University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 65 years and older
- Diagnosed with AD according to DSM-IV diagnostic criteria by a neurologist,
- MOCA ≥ 13
- Clinical Dementia Rating Scale < 2
- Having sufficient wireless support or telephone connection where the person lives
- Who gave consent to participate in the study
- No history of any neurological or orthopedic injury that could prevent participation in the study and affect functional mobility.
Exclusion Criteria:
- Geriatric Depression Scale score > 11
- Various mobility restrictions, musculoskeletal disorders, (wheelchair use, etc.)
- Clinically significant aphasia (must be able to understand the therapist's commands)
- Significant visual or sensory impairment
- MoCA < 13
- Having a severe musculoskeletal disorder
- Having paralysis
- Impaired balance
- The presence of severe lung and heart disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Physical exercise and computerized cognitive stimulation
Supervised Physical Exercise Program (SPEP) sessions will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed. The Computerized Cognitive Stimulation Program (CCSP) (Beynex) will be planned for 12 weeks, 5 days a week, approximately 10 minutes, for a total of 40 sessions. Fisrtly, the use of CCSP will be demonstrated to the patients. Then, it will be given as home program. While the patients play the games in CCSP via their smartphones, their caregivers will be informed in detail about accompanying the patients if they need it. The follow-up of cognitive stimulation will be made with the person accompanying the patient over the phone. Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week). |
SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour.
The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
|
|
Experimental: physical exercise
SPEP sessions will be demonstrated to individuals by a 6-year-experienced physiotherapist via videoconference (Zoom Inc.) and the exercises will be performed simultaneously online together with the physiotherapist and the patient. Participants will be able to do the exercises together with their caregivers if needed. Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week). |
SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
|
|
No Intervention: control
The individuals included in this group will be informed that they should continue their normal daily life activities. Individuals will be evaluated by a physiotherapist who will perform the assessment at pre-treatment, post-treatment (12th week) and follow-up period (24th week). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Alzheimer's Disease Related Quality of Life Scale
Time Frame: 24 weeks
|
This scale evaluates health-related quality of life in individuals with AD.
The scale includes 40 questions in total and examines 5 quality of life domains (A-Social Interaction, B-Self Awareness, C-Affect and Mood, D- Enjoying Activities, E-Interaction with the Environment).
|
24 weeks
|
|
Montreal Cognitive Assessment Scale
Time Frame: 24 weeks
|
MOCA is a short cognitive assessment method developed to detect particularly mild stages of cognitive impairment.
|
24 weeks
|
|
Berg Balance Scale
Time Frame: 24 weeks
|
Berg Balance Scale measures static and dynamic balance in elderly individuals.
|
24 weeks
|
|
Time up and Go Test
Time Frame: 24 weeks
|
TUG test evaluates fall risk, mobility and physical performance in the elderly
|
24 weeks
|
|
Sit to Stand Test
Time Frame: 24 weeks
|
Sit-to-stand test will be performed on an armless chair with a height of 46 cm to determine the physical fitness level of elderly individuals
|
24 weeks
|
|
Arm Curl Test
Time Frame: 24 weeks
|
The Arm Curl test is one of the subtests of the Senior fitness test and it is performed to evaluate upper extremity muscle strength
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Katz Activities of Daily Living Scale
Time Frame: 24 weeks
|
Katz ADLs consist of six questions that include information about bathing, dressing, toilet, movement, excretion, and feeding activities.
|
24 weeks
|
|
Lawton Instrumental Activities of Daily Living Scale
Time Frame: 24 weeks
|
Lawton IADL scale consists of 8 items and a single subscale.
In addition, it consists of eight questions about using the phone, preparing meals, shopping, doing daily household chores, washing clothes, getting on the transportation vehicle, taking medicines and money management
|
24 weeks
|
|
Geriatric Depression Scale (Short Form)
Time Frame: 24 weeks
|
The GDS Short Form (GDS-15) is a 15-item scale that is used for the diagnosis of depression in elderly individuals
|
24 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- COVID-19
- Alzheimer Disease
Other Study ID Numbers
- 25.03.2021/37
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of California, Los AngelesRecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s DementiaUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Heinrich-Heine University, DuesseldorfNot yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)Germany
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Not yet recruiting
-
Xuanwu Hospital, BeijingEnrolling by invitation
-
Beijing Tiantan HospitalNot yet recruiting
-
Danyang Huichuang Medical Equipment Co., Ltd.RecruitingAlzheimer s DiseaseChina
Clinical Trials on Physical exercise and computerized cognitive training
-
The Hong Kong Polytechnic UniversityUniversity of Santo TomasUnknownMild Cognitive ImpairmentPhilippines
-
University of Alabama at BirminghamPulmonary Fibrosis FoundationCompletedIdiopathic Pulmonary FibrosisUnited States
-
Chang Gung Memorial HospitalRecruitingCognitive Deficit | Trauma, BrainTaiwan
-
Chang Gung Memorial HospitalUnknown
-
Istituto Nazionale di Ricovero e Cura per AnzianiFondazione Cariverona, ItalyWithdrawn
-
Chang Gung Memorial HospitalRecruitingStroke | Mild Cognitive ImpairmentTaiwan
-
Montreal Heart InstituteCompletedCardiovascular DiseasesCanada
-
University Medical Centre LjubljanaCompletedChronic Kidney Diseases | Cognitive Dysfunction | Physical InactivitySlovenia
-
Ruijin HospitalRenJi Hospital; Huashan Hospital; Shanghai General Hospital, Shanghai Jiao Tong...UnknownCognitive DysfunctionChina